Kramer-Drauberg M, Petrini E, Mira A, Patrucco E, Scardaci R, Savinelli I
Mol Oncol. 2025; 19(2):311-328.
PMID: 39838816
PMC: 11793020.
DOI: 10.1002/1878-0261.13798.
Benary G, Kilgenstein F, Koller S, Scherkenbeck J
RSC Adv. 2025; 15(2):883-895.
PMID: 39802464
PMC: 11719397.
DOI: 10.1039/d4ra08503e.
Vithani N, Zhang S, Thompson J, Patel L, Demidov A, Xia J
J Chem Inf Model. 2024; 64(21):8258-8273.
PMID: 39419500
PMC: 11558672.
DOI: 10.1021/acs.jcim.4c01435.
Ghadrdoost Nakhchi B, Kosuru R, Chrzanowska M
Int J Mol Sci. 2024; 25(18).
PMID: 39337337
PMC: 11432579.
DOI: 10.3390/ijms25189853.
Sabt A, Tawfik H, Khaleel E, Mustafa Badi R, Abdelsattar Ibrahim H, Elkaeed E
Mol Divers. 2024; 28(6):4581-4608.
PMID: 38289431
DOI: 10.1007/s11030-023-10777-6.
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith C, Chen D, Christensen J, Coulombe R, Fethiere J, Gunn R
J Med Chem. 2023; 67(1):774-781.
PMID: 38156904
PMC: 10788894.
DOI: 10.1021/acs.jmedchem.3c02140.
From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y, Liu Q, Xie H, Ding J
Acta Pharmacol Sin. 2023; 45(4):686-703.
PMID: 38049578
PMC: 10943119.
DOI: 10.1038/s41401-023-01194-4.
Small molecules targeting protein-protein interactions for cancer therapy.
Wu D, Li Y, Zheng L, Xiao H, Ouyang L, Wang G
Acta Pharm Sin B. 2023; 13(10):4060-4088.
PMID: 37799384
PMC: 10547922.
DOI: 10.1016/j.apsb.2023.05.035.
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Ketcham J, Haling J, Khare S, Bowcut V, Briere D, Burns A
J Med Chem. 2022; 65(14):9678-9690.
PMID: 35833726
PMC: 9340770.
DOI: 10.1021/acs.jmedchem.2c00741.
Conformations and binding pockets of HRas and its guanine nucleotide exchange factors complexes in the guanosine triphosphate exchange process.
Xiong Y, Zeng J, Xia F, Cui Q, Deng X, Xu X
J Comput Chem. 2022; 43(13):906-916.
PMID: 35324017
PMC: 9191747.
DOI: 10.1002/jcc.26846.
Covalent Fragment Screening Identifies Rgl2 RalGEF Cysteine for Targeted Covalent Inhibition of Ral GTPase Activation.
Bum-Erdene K, Ghozayel M, Xu D, Meroueh S
ChemMedChem. 2022; 17(6):e202100750.
PMID: 35061330
PMC: 9070689.
DOI: 10.1002/cmdc.202100750.
Drugging the undruggable: a computational chemist's view of KRAS.
Bodnarchuk M, Cassar D, Kettle J, Robb G, Ward R
RSC Med Chem. 2021; 12(4):609-614.
PMID: 34046632
PMC: 8128063.
DOI: 10.1039/d1md00055a.
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu H, Ye Z, Qin Y, Xu X, Yu X, Zhuo Q
Acta Pharmacol Sin. 2021; 42(11):1725-1741.
PMID: 33574569
PMC: 8563973.
DOI: 10.1038/s41401-020-00584-2.
Small molecule inhibitors of RAS proteins with oncogenic mutations.
Orgovan Z, Keseru G
Cancer Metastasis Rev. 2020; 39(4):1107-1126.
PMID: 32770300
PMC: 7680341.
DOI: 10.1007/s10555-020-09911-9.
Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyiri K, Koppany G, Vertessy B
Cancer Metastasis Rev. 2020; 39(4):1091-1105.
PMID: 32715349
PMC: 7680331.
DOI: 10.1007/s10555-020-09914-6.
Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers.
Mottini C, Cardone L
Int J Mol Sci. 2020; 21(14).
PMID: 32708716
PMC: 7404119.
DOI: 10.3390/ijms21145023.
Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets.
Cooley R, Kara N, Hui N, Tart J, Roustan C, George R
Wellcome Open Res. 2020; 5:20.
PMID: 32587898
PMC: 7308888.
DOI: 10.12688/wellcomeopenres.15675.1.
Current therapy of KRAS-mutant lung cancer.
Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J
Cancer Metastasis Rev. 2020; 39(4):1159-1177.
PMID: 32548736
PMC: 7680319.
DOI: 10.1007/s10555-020-09903-9.
RAS-targeted therapies: is the undruggable drugged?.
Moore A, Rosenberg S, McCormick F, Malek S
Nat Rev Drug Discov. 2020; 19(8):533-552.
PMID: 32528145
PMC: 7809886.
DOI: 10.1038/s41573-020-0068-6.
A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.
Ganaie A, Siddique H, Sheikh I, Parray A, Wang L, Panyam J
Mol Carcinog. 2020; 59(8):886-896.
PMID: 32291806
PMC: 7334075.
DOI: 10.1002/mc.23200.